{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Answers from the Lab","title":"Genetic Tests Identify Risk of Irinotecan-Induced Toxicity: John Logan Black, M.D.","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/6177a66f\"></iframe>","width":"100%","height":180,"duration":934,"description":"John Logan Black, M.D., explains how Mayo Clinic Laboratories' UGT1A1 tests (Mayo IDs: U1A1Q and UGTFZ) identify genetic variants that increase the risk of potentially life-threatening reactions to irinotecan, a chemotherapy agent.\n(00:32)\nCould you give us a brief overview about your background and yourself?\n \n(02:16)\nCould you explain the role of the UGT1A1 gene and its significance in the pharmacogenomics of irinotecan? \n \n(05:34)\nWhat specific tests do we offer for UGT1A1 at Mayo Clinic Laboratories?\n \n(08:01)\nCan you clarify the difference between targeted genotyping and full gene sequencing, and when each method is most appropriate?\n \n(10:36)\nCould you elaborate on the specific clinical indications for testing in relation to irinotecan?\n \n(13:27)\nHow do UGT1A1 test results impact the dosing of irinotecan? What should clinicians consider when using those results? \n \n(14:02)\nAre there any other factors or related genes that should be considered alongside UGT1A1, particularly for cancer therapy?","thumbnail_url":"https://img.transistorcdn.com/jhRCftFebxnTMwoIbA_WoqrSKwFRD_Y2kbh0JDjhx14/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lYjNj/ZDc0NTE0MWNlOWRl/YzRiN2Q3NDg2Mjg5/YWE4MS5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}